There were 437 press releases posted in the last 24 hours and 350,717 in the last 365 days.

Retrophin to Present at Upcoming Investor Conferences

/EIN News/ -- SAN DIEGO, May 24, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that the Company’s management team will present at the following upcoming investor conferences in June:

Jefferies 2018 Global Healthcare Conference
Date: Thursday, June 7, 2018
Time: 9:00 a.m. ET
Location: New York City

JMP Securities Life Sciences Conference
Date: Wednesday, June 20, 2018
Time: 1:30 p.m. ET
Location: New York City

Live webcasts will be available at and archived replays will be accessible for up to 30 days.
About Retrophin

Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.

Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications

Primary Logo